FNDC5 and pancreatic neoplasm: Liu et al. also treated MIA PaCa-2 and Panc03.27 pancreatic cancer cells with 0–100 nM of glycosylated and non-glycosylated irisin isoforms for 24, 48, and 72 h, observing a dose- and time-dependent reduction in MIA PaCa-2 viability, while Panc03.27 exhibited only a time-dependent effect [47].